For the Inventor, By the Inventor

Enter assignee name

Fort Worth, TX, United States of America

Nacuity Pharmaceuticals, Inc.

USPTO Granted Patents = 9

CIPO Patents = 1

EPO Patents = 2

Trademarks = 2

Forward Citations = 18

Loading Chart...

Loading Chart...

12 inventors (with patents filed for the assignee):

G Michael Wall (6 out of 13 patents)

Anja Rubenstein (2 out of 3 patents)

Rodney Tucker (2 out of 3 patents)

4. Josh Bolger (2 out of 3 patents)

5. Sambaiah Thota (2 out of 3 patents)

6. John W Lee (2 out of 3 patents)

7. Srinavasa Cheruku (2 out of 2 patents)

8. John Charles Warner (2 out of 49 patents)

9. Douglas Giles Johnson (1 out of 6 patents)

10. Doug Johnson (1 out of 2 patents)

11. Peter Anthony Campochiaro (1 out of 26 patents)

12. Daniel Hartman (1 out of 1 patent)

13. Lili Lu (2 patents)

14. Craig S Rosenfeld (0 patent)

15. John C Warner (0 patent)

9 patents: Sort by Forward Citations

1. 12472157 - Treatment of retinitis pigmentosa with n-acetylcysteine amide (2025-11-18),

2. 12458608 - N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement (2025-11-04),

3. 12245998 - N-acetylcysteine amide (NACA) and (2R,2R')-3,3′ disulfanediyl bis(2-acetamidopropanamide) (diNACA) for the prevention and treatment of radiation pneumonitis and treatment of pulmonary function in Cystic Fibrosis (2025-03-11),

4. 11766413 - Treatment of age-related macular degeneration, glaucoma, and diabetic retinopathy with n-acetylcysteine amide (NACA) or (2R,2R')-3,3′-disulfanediyl BIS(2-acetamidopropanamide)(DiNACA) (2023-09-26),

5. 11753370 - Methods of making deuterium-enriched N-acetylcysteine amide (d-NACA) and (2R, 2R')-3,3′-disulfanediyl bis(2-acetamidopropanamide) (diNACA) and using d-NACA and diNACA to treat diseases involving oxidative stress (2023-09-12),

6. 11548851 - Method for preparation of n-acetyl cysteine amide and derivatives thereof (2023-01-10),

7. 10590073 - Method for preparation of N-acetyl cysteine amide and derivatives thereof (2020-03-17),

8. 9889103 - Method for the preparation of N-acetyl cysteine amide (2018-02-13),

9. 9763902 - Method for preparation of N-acetyl cysteine amide (2017-09-19),

Nacuity Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapies for ophthalmic diseases. Our mission is to improve the lives of patients suffering from serious eye conditions through cutting-edge research and development. With a commitment to scientific excellence and patient well-being, we strive to bring new and effective treatments to market to address unmet medical needs in the field of ophthalmology.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

9 Patents

#80 in Fort Worth, TX

#2,011 in Texas

#31,659 in US

Fort Worth, TX, United States of America

Nacuity Pharmaceuticals, Inc.

Forward Citations = 18

12 inventors:

G Michael Wall (6 out of 13 patents)

Anja Rubenstein (2 out of 3 patents)

Rodney Tucker (2 out of 3 patents)

4. Josh Bolger (2 out of 3 patents)

5. Sambaiah Thota (2 out of 3 patents)

Please report any incorrect information to support@idiyas.com

Loading…